Cited 2 times in
Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.date.accessioned | 2024-01-03T01:46:12Z | - |
dc.date.available | 2024-01-03T01:46:12Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1738-3536 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197655 | - |
dc.description.abstract | Background: Effective treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis (FQr-MDR-TB) is difficult because of the limited number of available core anti-TB drugs and high rates of resistance to anti-TB drugs other than FQs. However, few studies have examined anti-TB drugs that are effective in treating patients with FQr-MDR-TB in a real-world setting. Methods: The impact of anti-TB drug use on treatment outcomes in patients with pulmonary FQr-MDR-TB was retrospectively evaluated using a nationwide integrated TB database (Korean Tuberculosis and Post-Tuberculosis). Data from 2011 to 2017 were included. Results: The study population consisted of 1,082 patients with FQr-MDR-TB. The overall treatment outcomes were as follows: treatment success (69.7%), death (13.7%), lost to follow-up or not evaluated (12.8%), and treatment failure (3.9%). On a propensity-score-matched multivariate logistic regression analysis, the use of bedaquiline (BDQ), linezolid (LZD), levofloxacin (LFX), cycloserine (CS), ethambutol (EMB), pyrazinamide, kanamycin (KM), prothionamide (PTO), and para-aminosalicylic acid against susceptible strains increased the treatment success rate (vs. unfavorable outcomes). The use of LFX, CS, EMB, and PTO against susceptible strains decreased the mortality (vs. treatment success). Conclusion: A therapeutic regimen guided by drug-susceptibility testing can improve the treatment of patients with pulmonary FQr-MDR-TB. In addition to core anti-TB drugs, such as BDQ and LZD, treatment of susceptible strains with later-generation FQs and KM may be beneficial for FQr-MDR-TB patients with limited treatment options. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한결핵 및 호흡기학회 | - |
dc.relation.isPartOf | TUBERCULOSIS AND RESPIRATORY DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hongjo Choi | - |
dc.contributor.googleauthor | Dawoon Jeong | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.contributor.googleauthor | Doosoo Jeon | - |
dc.contributor.googleauthor | Hee-Yeon Kang | - |
dc.contributor.googleauthor | Hee Jin Kim | - |
dc.contributor.googleauthor | Hee-Sun Kim | - |
dc.contributor.googleauthor | Jeongha Mok | - |
dc.identifier.doi | 10.4046/trd.2023.0040 | - |
dc.contributor.localId | A00057 | - |
dc.relation.journalcode | J02761 | - |
dc.identifier.eissn | 2005-6184 | - |
dc.identifier.pmid | 37254489 | - |
dc.subject.keyword | Fluoroquinolone | - |
dc.subject.keyword | Multidrug-Resistant | - |
dc.subject.keyword | Outcome | - |
dc.subject.keyword | Tuberculosis | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.citation.volume | 86 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 234 | - |
dc.citation.endPage | 244 | - |
dc.identifier.bibliographicCitation | TUBERCULOSIS AND RESPIRATORY DISEASES, Vol.86(3) : 234-244, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.